Generated by AI
FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases. Its current programs center on regenerative medicine and cell therapy applications for conditions such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. The company’s pipeline includes product candidates such as CYWC628, CYMS101, CYPS317, and CybroCell, which are being developed to address areas of significant unmet medical need. FibroBiologics also works with fibroblast cells and fibroblast-derived materials in research programs related to tissue regeneration and immune modulation. Based in Houston, Texas, FibroBiologics plays a specialized role in the biotechnology market by advancing cell-based approaches designed for therapeutic use across several disease areas.
Website455 East Medical Center Boulevard
Houston, TX, 77598
United States
The latest articles about FBLG.
Summary of Sep 1's posts. Generated by AI.
Summary of Jul 13's posts. Generated by AI.
No summary yet.
Summary of Apr 1's posts. Generated by AI.
Investors talking about FBLG also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.